NKTT 120

Drug Profile

NKTT 120

Alternative Names: NKT-14; NKTT120

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NKT-Therapeutics
  • Class Anti-inflammatories; Antianaemics; Monoclonal antibodies
  • Mechanism of Action T-lymphocyte subset inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Sickle cell anaemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Sickle-cell-anaemia in USA (IV)
  • 01 May 2015 NKT Therapeutics completes a phase-I trial in Sickle cell anaemia in USA (IV) (NCT01783691)
  • 08 Dec 2014 Efficacy and adverse event data from a phase Ib trial in Sickel cell anaemia presented at the 56th Annual meeting and exposition of the American Society of Hematology (ASH-Hem-2014)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top